CleverCap

Founder of Radiation Therapy Services, LLC (RTS), the largest provider of radiation therapy services in the United States, and has served as a director since 1988, and as President and Chief Executive Officer since April 1997.

Medical Director of the Carolina Urologic Research Center. Dr. Shore has conducted more than 250 clinical trials, focusing mainly on prostate and bladder disease. Dr. Shore is a Certified Physician Investigator who has numerous publications in peer-reviewed journals.

Retired Health Care Executive with 30 years experience with United Healthcare, CVS Caremark and Advocate Health Care

Dr. Malvehy brings a unique combination of clinical and business experience in healthcare to CleverCap. Prior to founding a successful medical practice focused on treating venous disease - an underserved condition - with cutting edge, minimally invasive techniques, Dr. Malvehy developed expertise managing complex medical problems and strategic healthcare issues.

Dr. Malvehy began his career as a Board Certified Emergency Physician in the Duke University Health System, serving as an attending physician caring for critically ill patients. In addition to teaching and supervising residency, medical students, physician assistants and nurses, Dr. Malvehy served on the Patient Care Committee, managing short- and long-term strategic patient care issues in the hospital setting. While maintaining his clinical responsibilities, he attended Duke University's Fuqua School of Business where he was a Bank of America Healthcare Scholar. Upon earning his MBA, Dr. Malvehy was recruited to Accuitive Medical Ventures and The Innovation Factory where he led diligence and portfolio management activities for two funds totaling $235 million. He successfully co-founded three medical device companies, two of which have products in active clinical trials currently. Dr. Malvehy was subsequently recruited to PwC (formerly PricewaterhouseCoopers) where he created, proposed and led healthcare strategy engagements for some of the world's largest medical device, pharmaceutical, insurance companies and hospitals.

Former President of Global Pharmaceuticals Division at Impax Laboratories. Over 20 years of pharmaceutical experience. He served as an Executive Vice President of Global Strategic Planning at Barr Pharmaceuticals Inc.

Kathryn is responsible for managing talent within the firm and at the senior executive level within Mainsail’s portfolio companies. She works closely with the Investment and Operations Teams at Mainsail as well as senior management teams to ensure the continued placement of exceptional candidates within Mainsail’s portfolio companies. She is also actively involved in business development efforts to enhance Mainsail’s network and identify new opportunities for portfolio companies.

Prior to joining Mainsail, Kathryn served as an advisor to funds and start ups in healthcare, IT and media, consulting on strategy and fundraising. In addition, she led deal sourcing on the West Coast for SightLine Partners, a fund focused on direct secondary investments in late stage medical technology companies. From 2005-2010, Kathryn worked for De Novo Ventures, a top quartile $650M healthcare fund. She sourced, evaluated and executed equity investments in early to late stage healthcare companies. In this role, she worked closely with portfolio companies, partnering with the CEOs and senior management teams on organizational design, recruiting talent, product positioning, sales strategy, IP and technology licensing deals, and financing strategies. Prior to De Novo, Kathryn worked for Merck & Co., Inc. in the US, Europe and Asia. She played a key role in the design, construction, commissioning and start up of a $400M bulk chemical manufacturing facility in Singapore, managing several cross-functional teams globally. Lastly, Kathryn worked at Genentech in strategic planning and operations strategy.

Kathryn is a graduate of the University of Notre Dame with Bachelor of Science degrees in Chemical Engineering and Biochemistry. She holds an M.B.A. from Harvard Business School.

James is a healthcare executive and entrepreneur whose experience spans numerous international markets. Having served in increasingly senior roles in the healthcare practices of KPMG, The Advisory Board Company and Standard & Poor's, James founded Fitzroy Health. James is also co-founder of Oncowell LLC, and currently sits on the Advisory Board of CleverCap. He was awarded Entrepreneur of the Year at The Wharton School 2009 WEC Expo and has been profiled by the Financial Times. James holds a B.A. from The University of Melbourne and M.B.A.s from The London Business School and Columbia Business School.

Founder of Rainmakers and serial entrepreneur in over 20 technology startups.

Stephen Cichy is a nationally known sales, marketing, managed care contracting and trade relations executive in the specialty pharmacy arena, with over 20 years of healthcare industry experience. Over the last several years, Mr. Cichy has assisted organic enterprise revenue growth of more than $1 billion, from concept to commercialization. Mr. Cichy is currently Founder and Managing Director of Monarch Specialty Group, Inc., a leading strategic advisor to mid-sized specialty and infusion pharmacies and pharmaceutical companies. Prior to founding Monarch Specialty Group, from March 2009 until May, 2012, Mr. Cichy was Executive Vice President of Sales, Marketing and Product Development at BioScrip, Inc. (NASDAQ: BIOS), a national specialty pharmacy and infusion service provider. In April, 2012 Mr. Cichy completed the successful divestiture of BioScrip’s specialty and mail service pharmacy businesses to Walgreens, a prescription drug retailer. Prior to joining BioScrip, from August 2007 until March 2009, Mr. Cichy was Vice President of Product Development for Walgreens, Inc. (NASDAQ: WAG). From April 2005 until September 2007, Mr. Cichy held various positions with Option Care, Inc., a specialty and infusion pharmacy provider, including Senior Director of Product Development and Vice President of Business Development and Commercial Operations. Option Care (formerly NASDAQ: OPTN) was acquired by Walgreens in September 2007 for $670 million. Prior to joining Option Care, from March 2003 to April 2005, Mr. Cichy was Managing Director of New Product Planning for Caremark, Inc., a pharmacy benefit management and specialty pharmacy company. Caremark (formerly NYSE: CMX) was sold in 2005 to CVS Corp. (NYSE: CVS) for $26.5 billion.